Orforglipron hemicalcium hydrate

Orforglipron hemicalcium hydrate (LY3502970 hemicalcium hydrate; GLP-1 receptor agonist 1 hemicalcium hydrate) represents the hemicalcium hydrate form of the calcium salt of Orforglipron, an orally active agonist targeting the Glucagon-like peptide-1 receptor (GLP-1R) . This compound has demonstrated efficacy in mitigating type 2 diabetes [1].

C[C@@H]1[C@](N2C3=CC=C([C@@H]4CC(C)(OCC4)C)C=C3C=C2C(N5[C@H](C6=C(N7C(N(C8=CC=C(N(N=C9)C)C9=C8F)C=C7)=O)N(C%10=CC(C)=C(C(C)=C%10)F)N=C6CC5)C)=O)(C([N-]%11)=NOC%11=O)C1.C[C@@H]%12[C@](N%13C%14=CC=C([C@@H]%15CC(C)(OCC%15)C)C=C%14C=C%13C(N%16[C@H](C%17=C(N%18C(N(C%19=CC=C(N(N=C%20)C)C%20=C%19F)C=C%18)=O)N(C%21=CC(C)=C(C(C)=C%21)F)N=C%17CC%16)C)=O)(C([N-]%22)=NOC%22=O)C%12.[Ca+2].O.O.O